These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28025931)

  • 1. A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States.
    Divers C; Platt D; Wang E; Lin J; Lingohr-Smith M; Mathai SC
    J Manag Care Spec Pharm; 2017 Jan; 23(1):92-104. PubMed ID: 28025931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
    Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
    J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanylate cyclase stimulators for pulmonary hypertension.
    Wardle AJ; Seager MJ; Wardle R; Tulloh RM; Gibbs JS
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011205. PubMed ID: 27482837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database.
    Burger CD; Pruett JA; Lickert CA; Berger A; Murphy B; Drake W
    J Manag Care Spec Pharm; 2018 Mar; 24(3):291-302. PubMed ID: 29406840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta-analysis.
    Chen X; Zhai Z; Huang K; Xie W; Wan J; Wang C
    Clin Respir J; 2018 Jun; 12(6):2065-2074. PubMed ID: 29393580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center.
    Sulica R; Fenton R; Cefali F
    Cardiol Ther; 2015 Dec; 4(2):209-18. PubMed ID: 26411969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial designs in PAH: shifting from functional measurements to long-term clinical outcomes.
    Studer SM; Gilkin RJ
    Am J Manag Care; 2014 Mar; 20(6 Suppl):S115-22. PubMed ID: 24716456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1191-1201. PubMed ID: 29083968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factor Profiles Achieved with Medical Therapy in Prevalent Patients with Pulmonary Arterial and Distal Chronic Thromboembolic Pulmonary Hypertension.
    Bartenstein P; Saxer S; Appenzeller P; Lichtblau M; Schwarz EI; Ulrich S
    Respiration; 2018; 96(2):127-137. PubMed ID: 29642071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
    McLaughlin VV; Jansa P; Nielsen-Kudsk JE; Halank M; Simonneau G; Grünig E; Ulrich S; Rosenkranz S; Gómez Sánchez MA; Pulido T; Pepke-Zaba J; Barberá JA; Hoeper MM; Vachiéry JL; Lang I; Carvalho F; Meier C; Mueller K; Nikkho S; D'Armini AM
    BMC Pulm Med; 2017 Dec; 17(1):216. PubMed ID: 29282032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic burden of chronic thromboembolic pulmonary hypertension in Russian Federation.
    Chazova IE; Martynyuk TV; Valieva ZS; Nakonechnikov SN; Nedogoda SV; Salasyuk AS; Taran IN; Gratsianskaya SE
    Ter Arkh; 2018 Sep; 90(9):101-109. PubMed ID: 30701743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs?
    Martínez Meñaca A; Blanco Vich I; López Meseguer M; López Reyes R; Bedate Díaz P; Elías Hernández T; Fernández-Cuesta Peñafiel I; Fernández G; Álvez Liste A; Escribano Subías P
    Adv Ther; 2021 Apr; 38(4):1860-1875. PubMed ID: 33675523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost to managed care of managing pulmonary hypertension.
    Said Q; Martin BC; Joish VN; Kreilick C; Mathai SC
    J Med Econ; 2012; 15(3):500-8. PubMed ID: 22313330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis.
    Chen Y; Li F; Luo J; Chen J; Luo P; Li J
    Can Respir J; 2021; 2021():1626971. PubMed ID: 34512819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension.
    van Thor MCJ; Ten Klooster L; Snijder RJ; Post MC; Mager JJ
    Int J Cardiol Heart Vasc; 2019 Mar; 22():163-168. PubMed ID: 30859124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Instrumental Characteristics of Newly Diagnosed Patients with Various Forms of Pulmonary Hypertension according to the Russian National Registry.
    Chazova IY; Martynyuk TV; Valieva ZS; Gratsianskaya SY; Aleevskaya AM; Zorin AV; Nakonechnikov SN
    Biomed Res Int; 2020; 2020():6836973. PubMed ID: 32626754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension.
    Kenny M; Clarke MM; Pogue KT
    J Pharm Pract; 2022 Jun; 35(3):437-444. PubMed ID: 33084500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.